Wealth Enhancement Advisory Services LLC Raises Stake in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Wealth Enhancement Advisory Services LLC lifted its position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 10.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,066 shares of the company’s stock after purchasing an additional 390 shares during the period. Wealth Enhancement Advisory Services LLC owned about 0.11% of Invesco Biotechnology & Genome ETF worth $271,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of PBE. Gerber Kawasaki Wealth & Investment Management boosted its position in shares of Invesco Biotechnology & Genome ETF by 3.0% during the fourth quarter. Gerber Kawasaki Wealth & Investment Management now owns 223,568 shares of the company’s stock worth $14,874,000 after acquiring an additional 6,527 shares during the last quarter. LPL Financial LLC grew its position in Invesco Biotechnology & Genome ETF by 1.7% in the fourth quarter. LPL Financial LLC now owns 92,105 shares of the company’s stock worth $6,128,000 after acquiring an additional 1,503 shares in the last quarter. Bank of America Corp DE increased its stake in Invesco Biotechnology & Genome ETF by 3.2% during the fourth quarter. Bank of America Corp DE now owns 68,973 shares of the company’s stock worth $4,589,000 after acquiring an additional 2,116 shares during the last quarter. Commonwealth Equity Services LLC lifted its position in Invesco Biotechnology & Genome ETF by 16.9% in the fourth quarter. Commonwealth Equity Services LLC now owns 26,002 shares of the company’s stock worth $1,730,000 after buying an additional 3,764 shares during the last quarter. Finally, Penobscot Investment Management Company Inc. lifted its stake in Invesco Biotechnology & Genome ETF by 2.4% in the fourth quarter. Penobscot Investment Management Company Inc. now owns 19,450 shares of the company’s stock worth $1,294,000 after purchasing an additional 450 shares during the last quarter.

Invesco Biotechnology & Genome ETF Stock Down 1.3%

Shares of Invesco Biotechnology & Genome ETF stock opened at $63.94 on Monday. The company has a market capitalization of $226.35 million, a PE ratio of 20.39 and a beta of 0.79. Invesco Biotechnology & Genome ETF has a 52 week low of $54.52 and a 52 week high of $72.84. The stock’s fifty day moving average is $61.52 and its two-hundred day moving average is $65.19.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.